DemethimmunomycinAlternative Names: L 683742
Latest Information Update: 30 May 2001
At a glance
- Originator Merck & Co
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 06 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
- 19 Jul 1996 New profile